JP2022518567A - 運動のために対象を保護する方法 - Google Patents
運動のために対象を保護する方法 Download PDFInfo
- Publication number
- JP2022518567A JP2022518567A JP2021543437A JP2021543437A JP2022518567A JP 2022518567 A JP2022518567 A JP 2022518567A JP 2021543437 A JP2021543437 A JP 2021543437A JP 2021543437 A JP2021543437 A JP 2021543437A JP 2022518567 A JP2022518567 A JP 2022518567A
- Authority
- JP
- Japan
- Prior art keywords
- subject
- exercise
- group
- muscle
- cfu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000036314 physical performance Effects 0.000 claims abstract description 13
- 230000002708 enhancing effect Effects 0.000 claims abstract description 7
- 230000001737 promoting effect Effects 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 22
- 208000029549 Muscle injury Diseases 0.000 claims description 14
- 210000003205 muscle Anatomy 0.000 claims description 14
- 206010049565 Muscle fatigue Diseases 0.000 claims description 10
- 230000001965 increasing effect Effects 0.000 claims description 10
- 206010061218 Inflammation Diseases 0.000 claims description 8
- 230000006378 damage Effects 0.000 claims description 8
- 230000004054 inflammatory process Effects 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 5
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 5
- 210000003734 kidney Anatomy 0.000 claims description 5
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 5
- 238000011084 recovery Methods 0.000 claims description 5
- 230000036542 oxidative stress Effects 0.000 claims description 3
- 235000016709 nutrition Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 6
- 230000002929 anti-fatigue Effects 0.000 abstract description 4
- 230000009931 harmful effect Effects 0.000 abstract 1
- 229940068196 placebo Drugs 0.000 description 19
- 239000000902 placebo Substances 0.000 description 19
- 206010016256 fatigue Diseases 0.000 description 11
- 102000004420 Creatine Kinase Human genes 0.000 description 9
- 108010042126 Creatine kinase Proteins 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 210000003127 knee Anatomy 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000013589 supplement Substances 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 6
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 102000003896 Myeloperoxidases Human genes 0.000 description 5
- 108090000235 Myeloperoxidases Proteins 0.000 description 5
- 150000005693 branched-chain amino acids Chemical class 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 102000016938 Catalase Human genes 0.000 description 4
- 108010053835 Catalase Proteins 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 102000002933 Thioredoxin Human genes 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 108060008226 thioredoxin Proteins 0.000 description 4
- 229940094937 thioredoxin Drugs 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108090001007 Interleukin-8 Proteins 0.000 description 3
- 102100030856 Myoglobin Human genes 0.000 description 3
- 108010062374 Myoglobin Proteins 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 102100030840 AT-rich interactive domain-containing protein 4B Human genes 0.000 description 2
- 101000792935 Homo sapiens AT-rich interactive domain-containing protein 4B Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000037147 athletic performance Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 239000003962 counterfeit drug Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000002747 voluntary effect Effects 0.000 description 2
- OCUSNPIJIZCRSZ-ZTZWCFDHSA-N (2s)-2-amino-3-methylbutanoic acid;(2s)-2-amino-4-methylpentanoic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O OCUSNPIJIZCRSZ-ZTZWCFDHSA-N 0.000 description 1
- 108010078546 Complement C5a Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002270 ergogenic effect Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 230000008798 inflammatory stress Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000031261 interleukin-10 production Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000010254 physiological adaptation Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims (15)
- 有効量のラクトバチルスプランタルム亜種プランタルムPS128及びその担体を含む組成物を、それを必要とする対象へ投与することを含む、運動のために前記対象を保護する方法。
- 前記保護は、前記対象の筋肉損傷を防止することを含む、請求項1に記載の方法。
- 前記保護は、前記対象の運動疲労を軽減することを含む、請求項1に記載の方法。
- 前記対象の炎症を軽減することをさらに含む、請求項1に記載の方法。
- 前記対象の腎臓損傷を軽減することをさらに含む、請求項1に記載の方法。
- 前記対象の体力(physical strength)を増加することをさらに含む、請求項1に記載の方法。
- 前記対象の身体能力(physical capacity)を増加することをさらに含む、請求項1に記載の方法。
- 前記対象の持久力を増加することをさらに含む、請求項1に記載の方法。
- 前記対象の筋肉疲労を軽減することをさらに含む、請求項1に記載の方法。
- 前記対象における酸化ストレスを軽減することをさらに含む、請求項1に記載の方法。
- 前記対象の身体パフォーマンス(physical performance)を増強することをさらに含む、請求項1に記載の方法。
- 前記対象の筋力回復を促進することをさらに含む、請求項1に記載の方法。
- 前記ラクトバチルスプランタルム亜種プランタルムPS128は、前記対象に1日あたり少なくとも109CFUの量で投与される、請求項1に記載の方法。
- 前記組成物は、栄養組成物又は医薬組成物である、請求項1に記載の方法。
- 前記組成物は、経口投与用に調製される、請求項1に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962797720P | 2019-01-28 | 2019-01-28 | |
US62/797,720 | 2019-01-28 | ||
PCT/CN2020/073752 WO2020156417A1 (en) | 2019-01-28 | 2020-01-22 | Method for protecting a subject for exercise |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022518567A true JP2022518567A (ja) | 2022-03-15 |
JP7433327B2 JP7433327B2 (ja) | 2024-02-19 |
Family
ID=71841673
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021543437A Active JP7433327B2 (ja) | 2019-01-28 | 2020-01-22 | 対象の運動疲労を軽減するための組成物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US11612624B2 (ja) |
EP (1) | EP3918054A4 (ja) |
JP (1) | JP7433327B2 (ja) |
CN (1) | CN113302280B (ja) |
BR (1) | BR112021014527A2 (ja) |
TW (1) | TWI739291B (ja) |
WO (1) | WO2020156417A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116367847A (zh) * | 2020-10-22 | 2023-06-30 | 李旺祚 | 用于治疗芳香族l-氨基酸脱羧基酶缺乏症的乳酸菌 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015213501A (ja) * | 2014-04-23 | 2015-12-03 | 國立陽明大學 | 乳酸菌、それを含む組成物及びそれらの使用 |
WO2018014225A1 (en) * | 2016-07-19 | 2018-01-25 | Bened Biomedical Co., Ltd. | Method for preventing or treating movement disorders with lactic acid bacterium |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10188684B2 (en) * | 2015-04-20 | 2019-01-29 | National Yang-Ming University | Method for preventing or treating functional gastrointestinal disorder by lactic acid bacterium |
TWI623319B (zh) * | 2016-07-19 | 2018-05-11 | 益福生醫股份有限公司 | 利用乳酸菌預防或治療運動障礙之方法 |
TWI583388B (zh) * | 2016-08-24 | 2017-05-21 | 國立體育大學 | 胚芽乳酸桿菌用於製備改善運動表現及降低肌肉疲勞之益生菌組合物之用途 |
-
2020
- 2020-01-22 TW TW109102570A patent/TWI739291B/zh active
- 2020-01-22 CN CN202080006943.9A patent/CN113302280B/zh active Active
- 2020-01-22 WO PCT/CN2020/073752 patent/WO2020156417A1/en unknown
- 2020-01-22 US US17/285,983 patent/US11612624B2/en active Active
- 2020-01-22 EP EP20747894.2A patent/EP3918054A4/en active Pending
- 2020-01-22 BR BR112021014527-3A patent/BR112021014527A2/pt unknown
- 2020-01-22 JP JP2021543437A patent/JP7433327B2/ja active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015213501A (ja) * | 2014-04-23 | 2015-12-03 | 國立陽明大學 | 乳酸菌、それを含む組成物及びそれらの使用 |
WO2018014225A1 (en) * | 2016-07-19 | 2018-01-25 | Bened Biomedical Co., Ltd. | Method for preventing or treating movement disorders with lactic acid bacterium |
Non-Patent Citations (4)
Title |
---|
BEHAVIOURAL BRAINRESEARCH, 2016, VOL.298, P.202-209, JPN6022033234, ISSN: 0005133483 * |
BRAIN RESEARCH,2016, VOL.1631, P.1-12, JPN6022033233, ISSN: 0005133482 * |
CHINESE JOURNAL OF PHYSIOLOGY, 2018, VOL.61, P.163-170, JPN6022033237, ISSN: 0005133485 * |
NUTRIENTS, 2016,VOL.8, 205, JPN6022033236, ISSN: 0005133484 * |
Also Published As
Publication number | Publication date |
---|---|
WO2020156417A1 (en) | 2020-08-06 |
TWI739291B (zh) | 2021-09-11 |
TW202037374A (zh) | 2020-10-16 |
EP3918054A1 (en) | 2021-12-08 |
JP7433327B2 (ja) | 2024-02-19 |
US20210338750A1 (en) | 2021-11-04 |
CN113302280B (zh) | 2024-05-24 |
US11612624B2 (en) | 2023-03-28 |
BR112021014527A2 (pt) | 2021-10-13 |
CN113302280A (zh) | 2021-08-24 |
EP3918054A4 (en) | 2022-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Stegen et al. | Physical fitness in morbidly obese patients: effect of gastric bypass surgery and exercise training | |
Guglielmo et al. | Effects of strength training on running economy | |
Kolden et al. | A pilot study of group exercise training (GET) for women with primary breast cancer: feasibility and health benefits | |
Kelly et al. | Novel, high-intensity exercise prescription improves muscle mass, mitochondrial function, and physical capacity in individuals with Parkinson's disease | |
Aagaard et al. | Mechanical muscle function, morphology, and fiber type in lifelong trained elderly | |
Nash et al. | Circuit resistance training improves the atherogenic lipid profiles of persons with chronic paraplegia | |
Bryant et al. | Neuromuscular adaptations and correlates of knee functionality following ACL reconstruction | |
Shephard | The case for increased physical activity in chronic inflammatory bowel disease: a brief review | |
Billinger et al. | Single limb exercise: pilot study of physiological and functional responses to forced use of the hemiparetic lower extremity | |
Ball et al. | Effect of muscle action, load and velocity variation on the bilateral neuromuscular response | |
Duque et al. | Physical deconditioning in chronic low back pain. | |
JP2022518567A (ja) | 運動のために対象を保護する方法 | |
Balraj et al. | Impact of retro-walking on pain and disability parameters among chronic osteoarthritis knee patients | |
Martinopoulou et al. | Evaluation of the isometric and dynamic rates of force development in multi-joint muscle actions | |
Pluskiewicz | Skeletal consequences in patients after stroke | |
Harbo et al. | Muscle performance relates to physical function and quality of life in long‐term chronic inflammatory demyelinating polyradiculoneuropathy | |
Herda et al. | Effects of a supplement designed to increase ATP levels on muscle strength, power output, and endurance | |
He et al. | Effects of High-Load Bench Press Training with Different Blood Flow Restriction Pressurization Strategies on the Degree of Muscle Activation in the Upper Limbs of Bodybuilders | |
Agre et al. | Neuromuscular rehabilitation and electrodiagnosis 4. Specialized neuropathy | |
LaRoche | Initial neuromuscular performance in older women influences response to explosive resistance training | |
Georgeson et al. | Body Composition Change Over a Professional Rugby League Season and Relationship to Rates and Types of Injury: 864: June 1 3: 45 PM-4: 00 PM | |
Ito et al. | Low-frequency high-intensity interval training improves maximal cardiorespiratory function and exercise performance in athletes | |
TWI847318B (zh) | 用於預防或最小化運動所引起的肌肉損傷的乳酸菌及方法 | |
Boisgontier et al. | Superimposed electrical stimulation comfortably improves the endurance of maximal voluntary contractions. | |
CÓRDOVA et al. | Effect of the Immunomodulator (AM3®) on Biochemical Muscular Damage Markers in Basketball Players. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210727 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220809 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221109 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230322 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230620 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230822 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240123 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240206 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7433327 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |